Medifast, Inc. (NYSE:MED) reported a significant EPS of $0.1029, outperforming the anticipated loss.
The company’s revenue reached approximately $140.2 million, surpassing estimates and indicating robust sales performance.
Financial health indicators such as a current ratio of 3.11 and a debt-to-equity ratio of 0.09 highlight MED’s strong financial position.

Medifast, Inc. (NYSE:MED) is a renowned entity in the health and wellness sector, rivalling firms like Nutrisystem and Weight Watchers. On November 4, 2024, MED unveiled its quarterly earnings, demonstrating a robust performance that surpassed market forecasts.

MED announced earnings per share (EPS) of $0.1029, exceeding the projected loss of $0.28. This accomplishment is particularly noteworthy against the Zacks Consensus Estimate, which had predicted a loss of $0.15 per share. Despite this positive outcome, the EPS represents a decrease from the prior year’s $2.12 per share, signaling challenges in sustaining previous profitability levels.

The company also disclosed revenue of approximately $140.2 million, outdoing the anticipated $134.2 million. This revenue achievement underscores MED’s capability to exceed sales expectations, as emphasized by Zacks. The price-to-sales ratio of 0.31 implies that investors are paying 31 cents for every dollar of sales, indicating a relatively modest valuation in relation to sales.

MED’s financial robustness is further evidenced by a strong current ratio of 3.11, showcasing its ability to meet short-term obligations with current assets. The debt-to-equity ratio of 0.09 reveals a minimal level of debt relative to equity, suggesting a prudent leveraging strategy. Moreover, the enterprise value to sales ratio of 0.16 and enterprise value to operating cash flow ratio of 2.70 offer insights into the company’s valuation in comparison to its sales and cash flow.